A Phase II Study of Neo-Adjuvant Gemcitabine, Cisplatin and Bevacizumab in Stage IIIA (N2) Non-Squamous Cell Non-Small Cell Lung Cancer

NCT00924209 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

7

Enrollment

NIH

Sponsor class

Stopped Study was terminated due to poor accrual.

Conditions

NSCLC
Stage IIIA (N2)

Interventions

DRUG: Gemcitabine
DRUG: Cisplatin
DRUG: Bevacizumab
PROCEDURE: Surgery
DRUG: Etoposide

Sponsor

National Cancer Institute (NCI)